Coherus Oncology, Inc.
CHRS evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Market Cap:
- $186.9M
- Lead Asset:
- casdozokitug (Phase 2)
What it means
What to watch
Prepared research question
What matters most for CHRS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CHRS
Coherus Oncology, Inc. is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a mid-stage pipeline targeting liver, head and neck, colorectal and other cancers.
Key risk: Cash burn rate
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 7 clinical trials for Coherus Oncology, Inc..
Coherus Oncology, Inc. is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a mid-stage pipeline targeting liver, head and neck, colorectal and other cancers.
- LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 [news · 2026-03-10].
- Cash & equivalents were $82.9M as of 2026-06-30, with total revenue of $14.3M and net income of -$20.6M [sec].
- Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 [news · 2026-03-10].
- Pipeline includes mid-stage clinical candidates casdozokitug (HCC) and tagmokitug, with key data readouts expected in H2 2026–H1 2027 [news · 2026-07-29].
- CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer [news · 2025-11-06].
What works
- LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024, indicating growing commercial traction [news · 2026-03-10].
- Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025, strengthening the balance sheet [news · 2026-03-10].
- Cash & equivalents of $82.9M as of 2026-06-30 provide a runway for ongoing operations and pipeline development [sec].
What to weigh
- Net income was -$20.6M as of 2026-06-30, reflecting ongoing operating losses [sec].
- Cash & equivalents declined from $191.7M in Q3 2025 to $82.9M as of 2026-06-30, indicating significant cash burn [news · 2025-11-06] [sec].
- Key pipeline catalysts for tagmokitug and casdozokitug are pending, with associated clinical and dilution risk [news · 2026-08-19].
From the filings
Quoted directly from source documents.
Risks & what to watch (3)›
Key risks
- Cash burn rate — Cash & equivalents fell from $191.7M (Q3 2025) to $82.9M (2026-06-30), indicating high cash consumption [news · 2025-11-06] [sec].
- Pipeline execution risk
- Dilution risk
What to watch
- Tagmokitug and casdozokitug data readouts in H2 2026–H1 2027 [news · 2026-07-29].
- LOQTORZI revenue growth trajectory and market penetration [news · 2026-03-10].
- Cash runway and any additional financing or partnership announcements [sec].
- Progress of CHS-114 clinical program in colorectal cancer [news · 2025-11-06].
Sources: Catalysts · News · SEC MD&A · Generated October 1, 2026 · How we verify sources →
Run Coherus Oncology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Coherus Oncology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.14 · 0% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
156
Total value held
$95.5M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 10,365,074 | $17.5M |
| vanguard capital management llc | 5,452,762 | $9.2M |
| samsara biocapital, llc | 3,428,571 | $5.8M |
| geode capital management, llc | 3,121,578 | $5.3M |
| kohlberg kravis roberts & co. l.p. | 3,036,076 | $5.1M |
| state street corp | 2,325,859 | $3.9M |
| two sigma investments, lp | 2,302,001 | $3.9M |
| alyeska investment group, l.p. | 2,250,000 | $3.8M |
| cm management, llc | 2,100,000 | $3.5M |
| tang capital management llc | 1,886,748 | $3.2M |
Showing top 10 of 156 institutional holders of Coherus Oncology, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 19.1%
- Days to cover
- 29.3
- Shares short
- 27,818,409
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CHRS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Coherus Oncology, Inc.?
Coherus Oncology, Inc. is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a mid-stage pipeline targeting liver, head and neck, colorectal and other cancers.
What is Coherus Oncology, Inc.'s lead drug candidate?
Coherus Oncology, Inc.'s most advanced tracked candidate is casdozokitug (Phase 2) for Hepatocellular Carcinoma.
Who is the CEO of Coherus Oncology, Inc.?
Mr. Dennis M. Lanfear is the chief executive officer of Coherus Oncology, Inc. (CHRS).
Where is Coherus Oncology, Inc. headquartered?
Coherus Oncology, Inc. (CHRS) is headquartered in Redwood City, CA, United States.
What therapeutic areas does Coherus Oncology, Inc. focus on?
Coherus Oncology, Inc. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.